Cooperative Agreement U48DP006872

The University of North Carolina at Chapel Hill (UNC-CH) received a $2,255,110 Cooperative Agreement award on September 4, 2025 from the National Cancer Institute (NCI) under the Cancer Centers Support Grants (CFDA 93.397) program. The award will support a Cancer Health Disparities SPORE (Specialized Programs of Research Excellence) in Endometrial Cancer, a multi-disciplinary translational research initiative aimed at studying biological and social factors driving disparities in endometrial...

This federal Cooperative Agreement award of $825,857 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) provides funding to Health Research, Inc. (d/b/a Health Research At Roswell Park) to serve as the Data and Resource Coordinating Center for the Cancer Immunoprevention Network (CIP-NET). The goal is to catalyze collaboration across CIP-NET and manage, integrate, and disseminate the data and resources generated through the network....

The University of Wisconsin System has been awarded a $2,490,206 Cooperative Agreement from the National Cancer Institute (CFDA 93.399 Cancer Control program) to operate the Cancer Prevention Clinical Trials Network (CP-CTNET) Coordinating Center. The Cooperative Agreement, with a performance period from August 5, 2025 to July 31, 2031, will support the design and conduct of early-phase clinical trials to assess the safety, tolerability, and cancer preventive potential of various agents and...

The National Cancer Institute (NCI) awarded a 5-year, $753,446 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to Boston Medical Center Corporation (BMC) to adapt and test an intervention to improve cervical cancer screening and follow-up in three diverse, underserved populations. The intervention combines education and quality improvement methods using performance improvement continuing medical education. It aims to decrease the overall burden of cervical...

The University of North Carolina at Chapel Hill received a $688,458 Project Grant award from the National Cancer Institute under the Cancer Cause and Prevention Research (CFDA 93.393) federal grant program. The award, which runs from September 15, 2025 to August 31, 2030, will investigate the use of 5-Fluorouracil (5FU) as an adjuvant therapy following thermal ablation to improve human papillomavirus (HPV) treatment outcomes among women living with HIV in Kenya. The study aims to evaluate the...

The University of North Carolina at Charlotte received a $150,784 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to investigate the relationship between the HSP70 chaperone protein and the cell cycle regulator cyclin D1/CLN3. The two-year project, running from September 2025 to August 2027, aims to characterize how post-translational modifications to HSP70 affect its interactions with cyclin D1 and CLN3, which are critical for cell cycle...

The University of California, San Francisco (UCSF) received a $724,840 Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393). The grant supports a multi-year research project to investigate the impact of persistent poverty on colorectal cancer risk, with a focus on elucidating the biological, behavioral, and place-based pathways. The research leverages data from two large U.S. cohort studies to assess associations...

The University of North Carolina at Chapel Hill was awarded a $197,747 Project Grant by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) to pilot and refine the "Improving Affordability in Cancer Care through Economic Screening and Support (I-ACCESS)" program. The objective is to develop a screening assessment and referral process to proactively identify cancer-related financial hardship in patients and connect them with education, counseling, and...

This Project Grant award of $357,694 from the National Cancer Institute (CFDA Program 93.393 - Cancer Cause and Prevention Research) aims to conduct research on health insurance disparities and their impact on cancer outcomes. The project, titled "Health Insurance and Disparities: More Than Access," will build on an established linkage between the Colorado Central Cancer Registry and the Colorado All-Payer Claims Database to analyze the role of plan type, patient demographics,...

The National Cancer Institute (NCI) awarded a $192,610 Project Grant under the Cancer Cause and Prevention Research Program (CFDA 93.393) to The University of Kentucky Research Foundation. This 24-month award, effective April 1, 2025, will evaluate the impact of social determinants of health (SDOH) on early-onset colorectal cancer (EOCRC) diagnosis, treatment delays, and survival, with a focus on underserved populations in Kentucky and Georgia. The project team will utilize an epidemiological...